A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029

Summary

Open-label, single dose, randomized, three-period, crossover design study to evaluate the effect of food on the bioavailability of a single oral dose of ASTX029 in healthy adult male and female participants. Following a screening period of up to 28 days, eligible participants will be enrolled and randomized to receive a single treatment (A, B, C) in a random order, with each treatment separated by an approximate 5-day washout period. The duration of the study is expected to be approximately 42 days.

Timeline

Start

2020-07-23

Primary completion

2020-10-01

Completion

2020-10-06

Drugs

Indications

No indication recorded.